Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 May;19(2):69-77.
doi: 10.1055/s-2006-942347.

Colorectal gastrointestinal stromal tumors: a brief review

Rishindra M Reddy  1 , James W Fleshman
Affiliations

Colorectal gastrointestinal stromal tumors: a brief review

Rishindra M Reddy et al. Clin Colon Rectal Surg. 2006 May.

Abstract

Gastrointestinal stromal tumors (GISTs) are rare lesions that constitute the majority of mesenchymal tumors in the gastrointestinal tract. Within the colon and rectum, they represent 0.1% of all cancers. They can present with a variety of symptoms but are often asymptomatic. Although many lesions may be benign, up to half of patients develop recurrent disease within a few years. Almost all GISTs contain a mutation in the c-kit tyrosine kinase that leads to its constitutive activation and results in cell proliferation. This discovery has led to the immunostaining of the c-kit antigen (CD117) to distinguish GISTs from other malignancies. Radiologic examinations can be helpful in initial diagnosis and staging. Surgery is the best treatment for cure, but recent advances have led to the use of imatinib mesylate, a tyrosine kinase inhibitor, to treat metastatic or unresectable disease, or both. There are currently many clinical trials available to help treat GISTs.

Keywords: CD117/c-kit; Gastrointestinal stromal tumors; colon cancer; imatinib mesylate; surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of c-kit tyrosine kinase. (Adapted from Figure from Novartis Glivec website.14)
Figure 2
Figure 2
Computed tomography of a rectal gastrointestinal stromal tumor. White arrows are directed at the lesion. (Courtesy of C.O. Menias, M.D., Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO.)
Figure 3
Figure 3
(A) Spindle cell variant. (B) Epithelioid variant. (Courtesy of H. Wang, M.D., Department of Pathology, Washington University School of Medicine, St. Louis, MO.)
Figure 4
Figure 4
Treatment algorithm combining surgery and imatinib. (From van der Zwan and DeMatteo. Adapted with permission from John Wiley and Sons.)
See this image and copyright information in PMC

References

    1. Pidhorecky I, Cheney R T, Kraybill W F, Gibbs J F. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. 2000;7:705–712. - PubMed
    1. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002;38(suppl 5):S39–S51. - PubMed
    1. Stout A P. Bizarre smooth muscle tumors of the stomach. Cancer. 1962;15:400–409. - PubMed
    1. Appelman H D. Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn't know. Am J Surg Pathol. 1986;10(suppl 1):83–99. - PubMed
    1. Mazur M T, Clark H B. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507–519. - PubMed